Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

NEO

N

NeoGenomics, Inc. (NEO)

NCM – Цена в реальном времени. Валюта: USD

8.75

+0.09 (1.04%)

При закрытии: May 12, 2026, 4:00 PM EDT

8.85

+0.10 (1.14%)

После закрытия: May 12, 2026, 5:57 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

NeoGenomics Reports First Quarter 2026 Results

NeoGenomics Reports First Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls.

Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript

Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

NeoGenomics Reports First Quarter 2026 Results

NeoGenomics Reports First Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

23.04.2026

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.